Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 76 clinical trials
Phase I Study of Hu8F4 in Patients With Advanced Hematologic Malignancies

This phase I trial studies the side effects and best dose of anti-PR1/HLA-A2 monoclonal antibody Hu8F4 (Hu8F4) in treating patients with malignancies related to the blood (hematologic). Monoclonal antibodies, such as Hu8F4, may interfere with the ability of cancer cells to grow and spread.

monoclonal antibodies
blast crisis
hematologic malignancy
cancer
leukemia
  • 17 views
  • 13 Oct, 2022
  • 3 locations
Vorinostat Dose-escalation After Allogeneic Hematopoietic Cell Transplantation

The objective of this study is to evaluate the maximum tolerated (MTD) of vorinostat used in combination with low-dose azacitidine after allogeneic hematopoietic cell transplantation (alloHCT) for prevention of relapse of childhood myeloid malignancies.

cell transplantation
azacitidine
vorinostat
transplant conditioning
graft versus host disease
  • 2 views
  • 04 Oct, 2022
  • 1 location
A Phase 1 Trial of CIML NK Cell Infusion for Myeloid Disease Relapse After Hematopoietic Cell Transplantation

This research study is studying cytokine induced memory-like natural killer (CIML NK) cells plus IL-2 in adult patients with Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS) and Myeloproliferative Neoplasms (MPN) who relapse after haploidentical hematopoietic cell transplantation (haplo-HCT). This study will also study CIML NK cell infusion combined with IL-2 …

flow cytometry
blast cells
fludarabine
cytarabine
leukemia
  • 4 views
  • 08 Jul, 2022
  • 2 locations
Reduced-Intensity Conditioning for the Prevention of Treatment-Related Mortality in Patients Who Undergo a Hematopoietic Stem Cell Transplant

This phase II clinical trial evaluates whether a modified modality of conditioning reduces treatment-related mortality (TRM) in patients who undergo a hematopoietic stem cell transplant (HSCT) for a hematological malignancy. HSCT is a curative therapy for many hematopoietic malignancies, however this regimen results in higher rates of TRM than other …

chemotherapy regimen
myeloid malignancy
fludarabine
leukemia
hematologic disorder
  • 0 views
  • 21 Apr, 2022
  • 1 location
CD34+ (Malignant) Stem Cell Selection for Patients Receiving Allogenic Stem Cell Transplant

) in chronic phase, accelerated phase or blast crisis; Acute Myelogenous Leukemia (AML); Myelodysplastic Syndrome (MDS); Juvenile Myelomonocytic Leukemia (JMML); Acute Lymphoblastic Leukemia (ALL); or

thiotepa
blast crisis
blast cells
fludarabine
blood stem cell transplant
  • 79 views
  • 01 Nov, 2021
  • 1 location
Reduced Intensity Chemotherapy and Radiation Therapy Before Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies

This clinical trial studies the use of reduced intensity chemotherapy and radiation therapy before donor stem cell transplant in treating patients with hematologic malignancies. Giving low doses of chemotherapy, such as cyclophosphamide and fludarabine phosphate, before a donor stem cell transplant may help stop the growth of cancer cells. It …

cytopenia
stem cell transplantation
chemotherapy regimen
blast cells
hematologic malignancy
  • 66 views
  • 29 Jun, 2022
  • 1 location
Hematopoietic Stem Cell Transplantation From Haploidentical Donors in Patients With Hematological Malignancies Using a Treosulfan-Based Preparative Regimen

This phase II trial studies how well a donor stem cell transplant, treosulfan, fludarabine, and total-body irradiation work in treating patients with blood cancers (hematological malignancies). Giving chemotherapy and total-body irradiation before a donor stem cell transplant helps stop the growth of cells in the bone marrow, including normal blood-forming …

stem cell transplantation
tyrosine
chronic lymphocytic leukemia
chemotherapy regimen
blast crisis
  • 2 views
  • 15 Oct, 2022
  • 1 location
211^At-BC8-B10 Before Donor Stem Cell Transplant in Treating Patients With High-Risk Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndrome, or Mixed-Phenotype Acute Leukemia

This phase I/II trial studies the side effects and best dose of 211^astatine(At)-BC8-B10 before donor stem cell transplant in treating patients with high-risk acute myeloid leukemia, acute lymphoblastic leukemia, myelodysplastic syndrome, or mixed-phenotype acute leukemia. Radioactive substances, such as astatine-211, linked to monoclonal antibodies, such as BC8, can bind to …

monoclonal antibodies
flow cytometry
stem cell transplantation
blast cells
acute leukemia
  • 20 views
  • 07 Oct, 2022
  • 1 location
Personalized NK Cell Therapy After Chemotherapy and Cord Blood Transplant in Treating Patients With Myelodysplastic Syndrome, Leukemia, Lymphoma or Multiple Myeloma

This phase II clinical trial studies how well personalized natural killer (NK) cell therapy works after chemotherapy and umbilical cord blood transplant in treating patients with myelodysplastic syndrome, leukemia, lymphoma or multiple myeloma. This clinical trial will test cord blood (CB) selection for human leukocyte antigen (HLA)-C1/x recipients based on …

flow cytometry
stem cell transplantation
tyrosine
blast cells
acute leukemia
  • 58 views
  • 05 Jul, 2022
  • 1 location
CD45RA Depleted Peripheral Stem Cell Addback for Viral or Fungal Infections Post TCRαβ/CD19 Depleted HSCT

The major morbidities of allogeneic hematopoietic stem cell transplant with non-human leukocyte antigen (HLA) matched siblings are graft vs host disease (GVHD) and life threatening infections. T depletion of the donor hematopoietic stem cell graft is effective in preventing GVHD, but immune reconstitution is slow, increasing the risk of infections. …

stem cell transplantation
myelodysplastic syndromes
acute leukemia
hematologic malignancy
bone marrow transplant
  • 0 views
  • 10 Apr, 2022
  • 1 location